Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia



Status:Completed
Conditions:Blood Cancer, Blood Cancer, Infectious Disease, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:55 - Any
Updated:9/29/2018
Start Date:December 2014
End Date:September 22, 2017

Use our guide to learn which trials are right for you!

An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra
supportive care measure after induction chemotherapy for patients with acute myeloid leukemia
(AML).

The prolonged period of severe neutropenia caused by induction chemotherapy for the treatment
of AML is associated with a nearly universal risk of febrile neutropenia. Standard supportive
care strategies include administration of prophylactic anti-bacterial and anti-fungal agents,
but serious breakthrough bacterial and fungal infections still occur. Granulocyte
colony-stimulating factor (G-CSF; filgrastim, Neupogen®) has been shown to shorten the
duration of severe neutropenia, fever, antibiotic use and hospitalization following induction
chemotherapy for AML. CLT-008, a human allogeneic myeloid progenitor cell product, is
intended to provide the cellular target for G-CSF to produce neutrophils during the period of
chemotherapy-induced bone marrow suppression when the patient's own progenitor cells may be
limited in responding to G-CSF. It is hypothesized that the production of allogeneic
neutrophils from CLT-008 will be sufficient to mitigate the infection-related consequences of
induction chemotherapy for AML.

Inclusion Criteria:

1. Acute myeloid leukemia arising de novo (per European LeukemiaNet)

2. Treated with any established chemotherapy regimen based on either:

1. 7+3: Standard-dose cytarabine 100-200 mg per meter squared continuous infusion
for 7 days with idarubicin 12 mg per meter squared or daunorubicin 45-90 mg per
meter squared for 3 days

2. High-dose cytarabine-based (HIDAC) chemotherapy administering a total cytarabine
dose of ≥ 4 g per meter squared alone or in combination with other anti-leukemic
agents (for example, anthracyclines, purine nucleoside inhibitors, etoposide,
etc.)

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening or by
the day chemotherapy is initiated

4. Adequate respiratory function with a room air oxygen saturation of at least 92%

5. Adequate cardiac function defined as an ejection fraction of at least 45%

6. Serum bilirubin ≤ 1.5 times the upper limits of normal. Subjects with a history of
Gilbert's syndrome may be enrolled if the total bilirubin is < 3 mg/dL with an
indirect bilirubin of > 1.5 mg/dL

7. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times
upper limits of normal prior to chemotherapy

8. Serum creatinine ≤ 2 times upper limits of normal or estimated glomerular filtration
rate ≥ 60 mL/min/1.73 meter squared per Modification of Diet in Renal Disease equation
(MDRD)

9. All subjects, except post-menopausal women, must be willing to utilize a highly
effective method of contraception throughout the study

10. Adequately informed of the nature and risks of the study with written informed consent

Exclusion Criteria:

1. Pregnant or breast feeding

2. Overt central nervous system manifestations of leukemia at diagnosis

3. Specifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection
(e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy
is initiated. "Uncontrolled" is defined as exhibiting ongoing signs and symptoms of
infection without improvement despite antimicrobial or other treatment.

4. AML subtype M3 (promyelocytic leukemia)

5. Previous chemotherapy for AML

6. History of or current human immunodeficiency virus (HIV) or hepatitis C virus
infection

7. History of or current clinically significant immunodeficiency

8. Known contraindication to receiving G-CSF

9. History of or current clinically significant alloimmunization to leukocyte antigens

10. Participation in another clinical study within 28 days of the day chemotherapy is
initiated, in which the study drug or device may influence hematopoiesis.
Co-enrollment in another study is allowed in cases where the investigational therapy
under study is a version of an acceptable chemotherapy regimen for this study per the
inclusion criteria.

11. Receiving any agent concurrently with CLT-008 infusion which inhibits cell division
(e.g., methotrexate or hydroxyurea)

12. Acute or chronic medical disorder that, in the opinion of the investigator or medical
monitor, may prevent the subject from completing participation in the study
We found this trial at
22
sites
Indianapolis, Indiana 46237
Principal Investigator: Luke P. Akard, MD
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Wendy Stock, MD
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Saar Gill, MD
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Melhem Solh, MD
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: John P. Galvin, MD, MS, MPH
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1801 West Taylor, Suite 1E
Chicago, Illinois 60612
312.355.1625
Principal Investigator: Irum Khan, MD
University of Illinois Cancer Center The University of Illinois Cancer Center is dedicated to reducing...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Gainesville, Florida 32608
Principal Investigator: Jack W. Hsu, MD
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Farhad Ravandi-Kashani, MD
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Principal Investigator: James M Foran, MD
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64218
Principal Investigator: Suman Kambhampati, MD
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Matthew Wieduwilt, MD, PhD
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Gary Schiller, MD
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Patrick J Stiff, MD
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Celalettin Ustun, MD
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Pinkal Desai, MD, MPH
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Martin Tallman, MD
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
4800 Friendship Avenue
Pittsburgh, Pennsylvania 15206
Principal Investigator: John Lister, MD
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
505 Parnassus Ave
San Francisco, California 94143
(415) 476-1000
Principal Investigator: Charalambos I. Andreadis, MD
University of California, San Francisco Medical Center UCSF Medical Center is recognized throughout the world...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: John Pagel, MD, PhD
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Valhalla, New York 10595
Principal Investigator: Delong Liu, MD, PhD
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
Worcester, Massachusetts 01655
Principal Investigator: Jan Cerny, MD, PhD
?
mi
from
Worcester, MA
Click here to add this to my saved trials